Medically reviewed by Erika Prouty, PharmD Key Takeaways There are two types of complement 3 glomerulopathy: dense deposit ...

Level up your pizza night with these fantastic Costco ingredients that make for excellent toppings, bases, and flavors for ...

Akebia Therapeutics is refocusing on Vafseo for dialysis patients, discontinuing expansion to non-dialysis, which has reset ...

What they've accomplished so far: The Rays have traded major players -- Shane Baz, Brandon Lowe, and Jake Mangum -- in two ...

GREEN BAY, Wis. (WSAW) - The Packers have added a two-time Pro Bowler to their defensive unit, reuniting Micah Parsons with former teammate Trevon Diggs. Diggs led the NFL with 11 interceptions in the ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...

Vertex could have several catalysts in 2026, helping it set a strong foundation for the future. DexCom is expanding its addressable market in order to help deal with some current challenges. Neither ...

Vertex could have several catalysts in 2026, helping it set a strong foundation for the future. DexCom is expanding its addressable market in order to help deal with some current challenges. Broader ...

Section 1. All executive departments and agencies of the Federal Government shall be closed and their employees excused from duty on Wednesday, December 24, 2025, and Friday, December 26, 2025, the ...

(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the ...

(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...